LECT-2 Amyloidosis: What do we Know?
- 1 February 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 70 (2) , 348-353
Abstract
Amyloidosis is a rare group of diseases characterized by abnormal folding of proteins and extracellular deposition of insoluble fibrils. It can be localized to one organ system or can have systemic involvement. The kidney is the most common organ to be involved in systemic amyloidosis often leading to renal failure and the nephrotic syndrome. The two most common types of renal amyloidosis are immunoglobulin light chain-derived amyloidosis (AL) and reactive amyloidosis (AA). A novel form of amyloidosis (ALECT2) derived from leukocyte chemotactic factor 2 (LECT-2) and primarily involving the kidneys was first described by Benson et al in 2008. The liver was subsequently identified as the second most common organ involved in ALECT2 amyloidosis. LECT-2 is a unique protein that can form amyloid deposits even in its unmutated form. Patients with ALECT2 present with minimal proteinuria in contrast to other forms of amyloidosis especially AL and AA. They may present with slightly elevated serum creatinine. Nephrotic syndrome and hematuria are rare. ALECT2 can be found in association with other types of amyloidosis as well as malignancies or autoimmune diseases. ALECT2 may be confused with amyloidosis associated with light and heavy chain monoclonal gammopathy if the immunofluorescence is positive with anti-light chain and anti-AA sera. The other organs involved are the duodenum, adrenal gland, spleen, prostate, gall bladder, pancreas, small bowel, parathyroid gland, heart, and pulmonary alveolar septa, but consistently uninvolved organs included brain and fibroadipose tissue. A renal biopsy along with characteristic features found on immunohistochemistry and mass spectrometry is diagnostic of ALECT2. ALECT2 should be suspected when all markers for AL and AA are negative. Proper diagnosis of ALECT2 can determine need for supportive care versus more aggressive interventions.Keywords
This publication has 45 references indexed in Scilit:
- Renal AmyloidosisClinical Journal of the American Society of Nephrology, 2013
- Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in miceJournal of Clinical Investigation, 2012
- The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic targetCancer Gene Therapy, 2011
- Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case SeriesAmerican Journal of Kidney Diseases, 2010
- Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsiesKidney International, 2010
- Prevalence and Origin of Amyloid in Kidney BiopsiesAmerican Journal of Surgical Pathology, 2009
- Leukocyte chemotactic factor 2: A novel renal amyloid proteinKidney International, 2008
- Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liverHepatology, 2004
- Molecular Cloning, Structural Characterization, and Chromosomal Mapping of the Human LECT2 GeneGenomics, 1998
- Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2Immunology Letters, 1996